Capstone Investment Advisors
MRVI icon

Capstone Investment Advisors’s Maravai LifeSciences MRVI Stock Holding History

Capstone Investment Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-61,780
Closed -$536K – 2316
2024
Q1 		$536K Sell
61,780
-11,635
-16% -$78.7K ﹤0.01% 1519
2023
Q4 		$481K Buy
73,415
+42,434
+137% +$274K ﹤0.01% 1358
2023
Q3 		$310K Buy
+30,981
New +$340K ﹤0.01% 1577

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capstone Investment Advisors's MRVI Position: Q2 2024 in Review

Capstone Investment Advisors sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 61,780 shares — an estimated $536K sold.

Capstone Investment Advisors first reported a position in MRVI in Q3 2023 and held it in 3 quarters. The position peaked at $536K in Q1 2024. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

  • Capstone Investment Advisors reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 61,780 Maravai LifeSciences shares in Q2 2024, an estimated $536K.
  • Capstone Investment Advisors first reported a position in Maravai LifeSciences in Q3 2023 and held it in 3 quarters.
  • Capstone Investment Advisors's Maravai LifeSciences position peaked at $536K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.